CBLL
CeriBell, Inc. Common StockCBLL
CBLL
About: CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
–
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
19%
upside
Avg. target
$33
24%
upside
High target
$36
34%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
TD Cowen Joshua Jennings 42% 1-year accuracy 8 / 19 met price target | 34%upside $36 | Buy Maintained | 9 Dec 2024 |
Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target | 23%upside $33 | Buy Maintained | 9 Dec 2024 |
JP Morgan Robbie Marcus 48% 1-year accuracy 10 / 21 met price target | 19%upside $32 | Overweight Initiated | 5 Nov 2024 |
B of A Securities Travis Steed 0% 1-year accuracy 0 / 5 met price target | 19%upside $32 | Buy Initiated | 5 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
1 month ago
CeriBell: Healthcare Technology Stock With A Promising Growth Outlook
Initiating coverage on CeriBell with a "Buy" rating, citing a promising growth outlook and a 24-month investment horizon. CeriBell's Ceribell System, an AI-powered EEG platform, shows strong revenue growth and high gross margins, indicating robust cash flow potential. The company targets a $2 billion addressable market, with plans for geographic expansion and diversification into other neurological conditions like delirium and ischemic stroke.
Neutral
GlobeNewsWire
1 month ago
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The fireside chat will take place on Thursday, November 21, 2024, at 10:00 a.m. Pacific Standard Time / 1:00 p.m. Eastern Standard Time.
Neutral
PRNewsWire
1 month ago
Ceribell to Report Third Quarter 2024 Financial Results on November 12, 2024
SUNNYVALE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Ceribell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 12, 2024.
Positive
Seeking Alpha
2 months ago
CeriBell: An Interesting EEG Play Going Public
CeriBell's IPO was highly successful, with shares rising 60%, but I'm cautious about investing after such a significant price increase. The company offers a revolutionary EEG platform for neurological conditions, showing strong growth while still incurring substantial losses. Despite impressive revenue growth, operating losses have increased so far in 2024, as the company has enough cash to sustain these losses.
Neutral
PRNewsWire
2 months ago
New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG
—Five abstracts presented at the 2024 Neurocritical Care Society Annual Meeting demonstrated the clinical impact of the FDA-cleared Ceribell System and Ceribell's AI-powered Clarity™ algorithm— —Clarity remains first and only device FDA 510(k) cleared for the diagnosis of electrographic status epilepticus— SUNNYVALE, Calif. , Oct. 16, 2024 /PRNewswire/ -- Ceribell, Inc. (Nasdaq: CBLL), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the presentation of data in five abstracts at the 2024 Neurocritical Care Society (NCS) Annual Meeting being held from October 14-17 in San Diego.
Neutral
PRNewsWire
2 months ago
CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SUNNYVALE, Calif. , Oct. 15, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced today the closing of its upsized initial public offering of 12,196,969 shares of its common stock at a public offering price of $17.00 per share, which includes 1,590,909 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares.
Neutral
Fast Company
2 months ago
CeriBell IPO: Stock price will be closely watched today as the AI brain-monitoring headband maker debuts on the Nasdaq
CeriBell, a neurodiagnostic startup known for its brain-monitoring headband that can detect seizure activity, is making its market debut on Friday in an IPO that is expected to generate $180.3 million in proceeds. Here's what to know about the medtech company and its initial public offering:
Positive
Market Watch
2 months ago
Ceribell's stock indicates up 35% in trading debut after pricing IPO at top of range
Ceribell Inc., a medical-device maker that uses artificial intelligence to monitor patient seizures, was on track for a strong trading debut Friday, after its initial public offering priced at the top of its proposed range.
Neutral
PRNewsWire
2 months ago
CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering
SUNNYVALE, Calif. , Oct. 10, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced today the pricing of its upsized initial public offering of 10,606,060 shares of its common stock at a public offering price of $17.00 per share.
Charts implemented using Lightweight Charts™